# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...
Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, includi...
Proposed acquisition extends Organon's international dermatology capabilities to the U.S.Organon has agreed to acquire Derm...
B of A Securities analyst Chi Fong maintains Roivant Sciences (NASDAQ:ROIV) with a Neutral and raises the price target from ...
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $...
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rat...